Regulatory Center
Meet the panel deciding the future of peptides
On July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) will publicly weigh whether seven peptides - including BPC-157, TB-500, KPV and MOTS-c - should gain a legal pathway into compounded medicine. Here is who sits on that panel, what they do, and the roles they bring to the review - with a source for every profile.
What this committee can - and can't - do
Section 503A of federal drug law lets licensed pharmacies compound customized medicines for individual patients. For a peptide that isn't part of an FDA-approved drug, getting onto the FDA's 503A Bulk Drug Substances List is the legal precondition for pharmacies to compound it under a prescription. The peptides under review were never on that list; in 2023 the FDA placed a group of them in "Category 2," reflecting significant safety concerns. The PCAC's vote is advisory and non-binding - it is a recommendation, and any actual change would still require a separate, formal rulemaking that can take more than a year.
Historically, PCAC panels reviewing peptides were composed largely of university academics and repeatedly declined to add peptide ingredients, citing risk, the Associated Press reported. The panel convened for the 2026 review includes more practicing clinicians and pharmacists. Each member's background and public affiliations are summarized below and linked to a source, so you can judge the panel for yourself.
The voting members
Gabriel Alizaidy, MD, MS
Scientific Director, Maximus Health - Coralville, IA
MD (Dow University of Health Sciences); MS in Precision Health (University of Chicago). Scientific director at a direct-to-consumer men's-health telehealth company; previously coordinated CAR-T oncology trials at UChicago Medicine.
Asare B. Christian, MD, MPH
Founder & Medical Director, Aether Medicine - Wayne, PA
MD (Medical College of Wisconsin); PM&R residency at Johns Hopkins; MPH (Harvard). Board-certified physiatrist practicing integrative pain and regenerative/longevity medicine; holds a faculty appointment at Penn's Perelman School of Medicine.
Timothy D. Fensky, RPh, DPh
President, Pharmacy Insights - Marlborough, MA
BS Pharmacy (Northeastern). 30+ years in Massachusetts pharmacy and an authority on USP compounding standards. Past President of the Massachusetts Board of Pharmacy and of the National Association of Boards of Pharmacy (NABP), which he represents on the committee.
Robert "Bobby" Harshbarger III, PharmD
Tennessee State Senator (District 4); pharmacist, Premier Pharmacy - Kingsport, TN
PharmD (Mercer University). Licensed pharmacist and operations manager at his family's compounding pharmacy; appointed to the Tennessee Board of Pharmacy and elected to the state senate in 2024.
Melissa Loseke, DO
Owner & Physician, Re-New Institute - Omaha, NE
DO (Des Moines University). Nearly two decades in pain management, hormone optimization and regenerative care; her clinic combines peptide therapy, hormone replacement, PRP and longevity medicine.
Haleem Mohammed, MD, MBA
Global Chief Medical Officer, Gameday Men's Health - Weston, FL
MD (UNIBE); Internal Medicine residency (Advocate Illinois Masonic); MBA (UMass). Board-certified internist who leads clinical strategy for a national men's-health clinic chain.
David D. Pope, PharmD
Chief Pharmacy Officer, XiFin Pharmacy Solutions - San Diego, CA
PharmD (University of Georgia); Certified Diabetes Educator. Pharmacy-technology entrepreneur (co-founder of STRAND Clinical Technologies, later part of OmniSYS and XiFin) and an advocate for pharmacist-provider policy.
Elizabeth Rebello, RPh, MD
Professor of Anesthesiology & Perioperative Medicine, UT MD Anderson Cancer Center - Houston, TX
BS Pharmacy (Houston) and MD (UT San Antonio); board-certified anesthesiologist. Serves on the USP Expert Compounding Committee - a technically central compounding voice on the panel - and chaired a prior PCAC meeting as Acting Chair.
Brian Serumaga, PhD
Director, Personalized Medicines, U.S. Pharmacopeia - Rockville, MD
BPharm (Makerere), MPH and PhD in pharmacoepidemiology (Nottingham); prior roles at Harvard and JSI. Represents USP on the committee and previously managed USP's compounding-standards work (chapters <795>/<797>).
Joshua Starbuck, MD
Founder & Physician, Makena Health - Wailea, HI
MD (Saba University); Internal Medicine residency (Tufts/Maine Medical Center). Board-certified internist and Institute for Functional Medicine-certified practitioner running a concierge longevity practice; holds a peptide-therapy certification (SSRP Institute).
Kris Wusterhausen, DO
Founder & Medical Director, The Resurge Clinic - Weatherford, TX
DO (UNT College of Osteopathic Medicine); board-certified in family medicine. Runs a clinic offering hormone replacement, peptide therapy and regenerative services, and is a peptide-therapy educator (International Peptide Society / SSRP).
Non-voting industry representative
Donnette D. Staas, PhD
VP, Regulatory Strategy, Jazz Pharmaceuticals - Philadelphia, PA
AB Chemistry (Columbia); PhD Chemistry (Harvard); MS Regulatory Affairs (Temple). ~25 years at Merck as a medicinal chemist and regulatory executive before joining Jazz. Holds the committee's formal, disclosed industry-interest seat and does not vote.
See how to weigh in before the vote →
Sources
Roster, terms and appointment dates: FDA - PCAC Roster (updated June 29, 2026), plus each member's FDA CV (linked on their card).
Meeting agenda, docket and logistics: FDA - July 23-24, 2026 PCAC Meeting.
Panel composition and background: Matthew Perrone, Associated Press (via PBS NewsHour), reporting on the reshaped FDA peptide advisory panel (July 2026).
Last updated July 9, 2026. Committee rosters can change before a meeting; verify the FDA page for the latest.